Krystal Biotech has patented a method using pharmaceutical compositions to deliver transgenes to the eye, correcting vision loss. The method involves administering a replication-defective herpes simplex virus type-1 with recombinant genome containing polynucleotides to enhance transgene levels in the eye. GlobalData’s report on Krystal Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Krystal Biotech, Oncolytic viruses was a key innovation area identified from patents. Krystal Biotech's grant share as of January 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Gene therapy for vision loss using hsv-1 virus
See Also:
A recently granted patent (Publication Number: US11865148B2) discloses a method for delivering a human transgene to the eye of a subject using a pharmaceutical composition containing a replication-defective herpes simplex virus type-1 (HSV-1) with a recombinant genome. The composition is administered topically or via injection to individuals with eye disorders associated with vision loss. The recombinant HSV-1 genome includes inactivating mutations in specific HSV-1 genes, ensuring reduced cytotoxicity compared to the wild-type virus.
The method involves the administration of the pharmaceutical composition, comprising the modified HSV-1 and the human transgene, to target cells in the eye of the subject. The recombinant HSV-1 genome contains mutations in genes like ICP4 and ICP22, crucial for efficient delivery of the transgene. The approach aims to address eye disorders by utilizing the replication-defective HSV-1 to safely and effectively deliver the therapeutic transgene to the eye, potentially offering a novel treatment option for vision-related conditions in humans.
To know more about GlobalData’s detailed insights on Krystal Biotech, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
